Novartis Ag (NVSEF) Enterprise Value (2009 - 2026)

Novartis Ag has disclosed Enterprise Value across 14 years of filings, most recently posting -$100.0 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$100.0 million, up 23.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$687.0 million (up 52.26% YoY), and the FY2025 annual result was -$2.7 billion, down 22.05% from the prior year.
• Enterprise Value came in at -$100.0 million for Q1 2026 at Novartis Ag, up from -$2.7 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$70.0 million in Q1 2022 to a low of -$2000.2 billion in Q1 2024.
• The 5-year median for Enterprise Value is -$2.2 billion (2024), against an average of -$122.6 billion.
• Across the five-year window, Enterprise Value plunged 769217.31% in 2024 and jumped 99.99% in 2025, its largest moves.
• Novartis Ag's Enterprise Value stood at -$18.9 billion in 2022, then gained by 23.78% to -$14.4 billion in 2023, then jumped by 84.47% to -$2.2 billion in 2024, then dropped by 22.05% to -$2.7 billion in 2025, then soared by 96.34% to -$100.0 million in 2026.
• The last three Enterprise Value figures came in at -$100.0 million (Q1 2026), -$2.7 billion (Q4 2025), and -$197.0 million (Q3 2025), per Business Quant data.